Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 18;10:1812. doi: 10.1038/s41467-019-09734-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — Inhibition and silencing of AURKB in cells and xenografts resistant to EGFR TKIs. a Western blot showing the dose-dependent decrease of pH3 levels induced by barasertib at 24 h in PC9-ER and PC9-GR4 cells. b ICC showing the inhibition of non-mitotic pH3 by barasertib and the MET/AXL/FGFR/AURKB inhibitor S49076 after 24 h in PC9-ER and PC9-GR4 cells. Scale bars indicate 20 μm. c Levels of AURKB mRNA (upper panel) and protein (lower panel) in clones with partial silencing of the AURKB gene (PC9-ER siAURKB1–3), compared to parental PC9-ER and PC9-ER cells transfected with a control lentivirus (PC9-ER siControl). Results shown are means ± SD of three independent determinations (n = 3) and asterisks indicate statistical significance (p < 0.05) in a two-sided Student’s t-test. d ICC showing the inhibition of non-mitotic pH3 in clones with partial silencing of the AURKB gene. Scale bars indicate 10 μm. e Dose-response curves to barasertib (left) and S49076 (right) of the parental PC9-ER and the PC-ER clones with partial silencing of AURKB. Values shown are means ± SD, experiments were conducted in tri (n = 3) or quadruplicates (n = 4). In each experiment, every concentration of drug was tested in sextuplicates (n = 6). f Effects of S49076 on the growth of subcutaneous PC9-ER (left panel) and PC9-GR4 (right panel) xenografts. Each point represents an individual tumor. Tumor dimensions were measured three times per week by digital calipers and volumes estimated according to the formula V = π/6 × L × W2, where L is the long axis and W is the short axis of tumor, respectively. Values are expressed as the fold-change in volume of each individual tumor after the 21 day treatment (n = 6 tumors per group). Lines indicated medians, and numbers correspond to levels of significance (p) in a Mann–Whitman U test. g H-scores of mitotic and non-mitotic pH3 in the tumor xenografts. Values shown are means ± SD (n = 6 tumors per group). H-scores of every tumor were evaluated independently by two expert pathologists (n = 2). h pH3 immunostaining of representative tumor xenografts